Pegylated interferon and ribavirin combination therapy is accepted as the standard antiviral treatment for chronic hepatitis C regardless of HCV genotype. This combination therapy achieves higher response rates than previous therapy, but, nevertheless, a large proportion of patients suffer from treatment failure or adverse events. Recent clinical studies of viral kinetics during antiviral treatment have led to the introduction of response-guided therapy, the concept of 'customized therapy depending on viral response', which focuses on modulation of the treatment period depending on the viral response to create a sustained viral response without unnecessary medication and costs. New upcoming direct-acting antivirals (DAAs) maximize response rate, and triple therapy including DAAs along with pegylated interferon and ribavirin combination therapy could soon be the standard therapy. In this article, we reviewed the factors affecting treatment, response guided treatment, retreatment after failure of standard treatment, management of adverse events during treatment, and new treatment options. (Korean J Hepatol 2012;18:22-28)
INTRODUCTION
Chronic hepatitis C affects an estimated 1-2% of the Korean population and is one of the leading causes of liver cirrhosis and hepatocellular carcinoma in Korea. 1 Over the past decade, pegylated interferon (peginterferon) and ribavirin combination therapy has become the standard antiviral treatment for chronic hepatitis C regardless of hepatitis C virus (HCV) genotype. Although standard peginterferon and ribavirin combination therapy achieves better response rates than previous interferon and ribavirin combination therapy or peginterferon monotherapy, a high proportion of patients still suffer from treatment failure or adverse effects of the therapy.
The recent results of clinical trials show that there has been much progress in the treatment of chronic hepatitis C.
Viral kinetics during antiviral treatment has emerged as an important predictor of treatment response and is used to guide treatment: the more rapidly HCV RNA disappears during treatment, the higher the response rate to treatment is.
This suggested that the viral response to treatment could be used to modify treatment duration. Response-guided therapy, the concept of 'customized therapy depending on viral response', which modifies the treatment period depending on the viral response, is a newly emerging 'proof of concept'. Shorter treatments would not only improve overall tolerability, but also reduce unnecessary medication and expense.
In this article, we reviewed recently updated American
Association for the Study of Liver Disease (AASLD) and 
Viral kinetics in chronic hepatitis C
Undetectable HCV RNA in a sensitive assay at treatment week 4 is referred to as rapid virological response (RVR). 4 A sensitive HCV RNA assay is defined as one with a lower limit of detection of 50 IU/mL. 4 It is known that the probability of a SVR is high regardless of viral genotype when RVR is attained. Although early termination of antiviral therapy may be considered in some selected patients with RVR, absence of RVR does not justify extending the duration of treatment because of its low predictability. [15] [16] [17] [18] An early virological response (EVR) is defined as a 2 log reduction of HCV RNA levels or the disappearance of 24 The other retrospective study of 343 patients reported that all patients with low HCV RNA levels before treatment and RVR after treatment attained SVR with 24 week short term therapy. 14 The recent EASL practice guidelines recommend 24 week therapy for patients who have low pre-treatment HCV RNA levels (400,000-800,000 IU/mL) and attain RVR. 4 Short term therapy can be considered selectively in genotype 1 patients with low baseline HCV RNA levels who achieve RVR when maintaining the therapy is difficult because of adverse effects (Fig. 1) .
However, additional prospective randomized control studies are needed in Korea.
In recent studies with genotype 2 and 3 chronic hepatitis showing DVR (Fig. 1) . 4 Another study obtained the opposite result 27 and there are no data in Korea yet.
Therefore, extended therapy for genotype 1 patients should be used with care, taking into account the patients' characteristics before treatment, adverse effects of treatment, compliance and socio-economic circumstances of the patients as well as virological responses to treatment.
EASL practice guidelines recommend 48 week extended therapy for genotype 2 and 3 patients with pEVR ( Fig. 1 ). Response-guided therapy in chronic hepatitis C. There is weak evidence that the algorithm for genotype 1 can also be applied to genotype 4, and there is also weak evidence that the algorithm for genotypes 2 and 3 can be applied to genotypes 5 and 6, excluding 12-16 week therapy. The dotted lines indicate weak evidence. PEG, pegylated; IFN, interferon; HCV, hepatitis C virus; RVR, rapid virological response.
responders after 48 week standard treatment (EPIC-3, REPEAT). The SVR rates after retreatment was as low as 6% in the EPIC-3 program and 9% in the REPEAT trial.
However, the SVR rates did increase significantly but only to 16% when 72 week extended treatment was performed in the REPEAT trial. 30 Interestingly, treatment success rates were relatively high in both the EPIC-3 and REPEAT trials when EVR was obtained after retreatment.
Two retrospective studies regarding the retreatment of Korean patients have been published as abstracts. The results in summary are as follows. Among patients who had used peginterferon and ribavirin, SVR rate was 0% (n=1) in the non-responders and 70% (n=10) in the relapsed patients.
Among patients who had used non-pegylated interferon and ribavirin, SVR rate was 17.6% (n=17) in non-responders and 81.3% (n=16) in relapsed patients. 31, 32 In conclusion, retreatment with peginterferon and ribavirin should be considered in patients who received nonpegylated interferon or peginterferon monotherapy. 2 However, when SVR is not attained despite an adequate period of treatment with peginterferon and ribavirin, careful consideration should precede retreatment with the same drugs. In Europe, retreatment is not recommended for nonresponders to standard therapy that includes peginterferon.
In such cases, triple combination therapy including a protease inhibitor which is expected to be released onto the market soon may be considered.
Management of adverse effects during treatment
Adverse effects associated with combination therapy with interferon and ribavirin are relatively frequent. It has been reported that 10-14% of patients discontinued treatment because of adverse effects. Neutropenia is defined as <1,500 neutrophils/mm 3 (ANC) and severe neutropenia is defined as ANC <500/mm 3 in 20, 33, 34 Granulocyte colony stimulating factor (G-CSF) is often used in severe neutropenic patients with fever after anti-cancer therapy, and has been shown to reduce mortality associated with infections. While a number of clinicians have tried using G-CSF in the antiviral therapy of chronic hepatitis C, cases other than hepatic cirrhosis patients requiring G-CSF are rare as severe infections are not common during the therapy even in cases of neutropenia. 35 In the studies that used 150-300 μg of G-CSF weekly, increase in ANC, not in SVR was demonstrated. 36, 37 As for platelets, it is recommended to halve the dose of peginterferon if they decline to <50,000/mm 3 and to discontinue peginterferon if they are <30,000/mm 3 . In a phase II clinical trial, eltrombopag, an oral thrombopoietin mimetic, was shown to increase platelet count in type C hepatic cirrhosis patients and significantly increased the number of patients who were able to complete 12 week antiviral treatment. 38 A phase III clinical trial is required to evaluate its effects on SVR.
New hepatitis C drugs
The most studied DAAs against hepatitis C virus are telaprevir (TVR) and boceprevir (BOC), which are NS3/4 protease inhibitor.
Although TVR induced rapid and extensive virus inhibition in 14 day monotherapy in phase I clinical trial (a 4.4 log reduction from that before treatment) and awakened great expectations, virological breakthrough due to the emergence of drug-resistant strains occurred in a number of patients who received it as monotherapy. Therefore trials to improve SVR by combining TVR with peginterferon and ribavirin have been undertaken. In the PROVE1 and PROVE2 trials, a marked increase of SVR was observed when this combination was used for the initial 12 weeks in treatment-naive genotype 1 patients (60-69% vs. 48%), and in the PROVE3 study, a notable increase of SVR was seen when the same treatment was used in treatment-experienced genotype 1 patients (51-53% vs. 14%). [39] [40] [41] BOC, a reversible covalent inhibitor of the NS3/4 protease similar to telaprevir, had a strong antiviral effect in vitro, and was effective when combined with peginterferon.
In patients with genotype 1 hepatitis C who had not responded to the initial therapies in phase I clinical trial, the combination of BOC with peginterferon decreased HCV RNA more effectively than monotherapy with BOC or peginterferon. 42, 43 Recently, the results of the comparison of triple therapy (BOC plus standard therapy) with standard therapy in 1097 patients with genotype 1 chronic hepatitis C have been reported (SPLINT-2 study). 42 In that trial, SVR rate for the 24 week and 44 week treatment groups receiving the boceprevir-containing regimen were 66% and 67%, respectively, which were significantly higher than the 40% in the standard therapy. The addition of BOC to peginterferonribavirin also resulted in significantly higher SVR rate than that of peginterferon-ribavirin alone in previously treated genotype 1 chronic hepatitis C patients (66% vs.
21%, respectively).
The use of BOC or TVR in combination with peginterferon alfa and ribavirin is accepted as the optimal therapy for genotype 1 in recently updated AASLD guideline. 
